The current study was done to investigate the anti-diabetic and anti-lipidemic properties of momodica charantia( bitter melon) fruit extract in alloxan diabetic rats treated for 4 weeks. At the end of the experimental period, several studies were performed including oral glucose tolerance test, serum insulin, blood glycated hemoglobin, liver glycogen, ALT, AST, lipid profiles to demonstrate the anti-diabetic and ant-lipidemic effect, in addition to in vitro and insitu studies as well as histopathological study to the suggest the possible mechanism of action of the plant. An oral hypoglycemic drug, rosiglitazone was used for comparison with bitter melon. Conclusion, bitter melon had a significant hypoglycemic an hypolipidemic effects when compared to rosiglitazone and this could be due to increase insulin release, increase glucose uptake and decrease glucose absorption.